Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma

  • Technology appraisal guidance
  • TA857
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence